Table 3.

Probabilities of End-of-Treatment Success under Several Bedaquiline Duration Strategies, endTB (Expand New Drug Markets for TB) Cohort, 2015–2018

	Unweighted Models			Weighted and Baseline Adjusted*
BDQ Duration	Unadjusted	Adjusted for Age and Sex	Baseline Adjusted*
	Prob. of Treatment Success (95% CI)	Prob. of Treatment Success (95% CI)	Prob. of Treatment Success (95% CI)	Prob. of Treatment Success (95% CI)
6 mo	0.88 (0.85–0.90)	0.87 (0.85–0.90)	0.85 (0.81–0.88)	0.85 (0.81–0.88)
7–11 mo	0.75 (0.71–0.80)	0.75 (0.71–0.80)	0.77 (0.73–0.81)	0.77 (0.73–0.81)
⩾12 mo	0.84 (0.82–0.87)	0.84 (0.82–0.87)	0.86 (0.83–0.88)	0.86 (0.83–0.88)

Definition of abbreviations: BDQ = bedaquiline; CI = confidence interval; Prob = probability.

All analyses shown here were conducted on the cloned data set and were therefore adjusted for immortal time bias.

^*The model was adjusted for age (years; continuous), sex, cumulative adherence > 80% (binary, with missing counted as ⩽80%), extensive disease (i.e., cavitary disease with a sputum smear result of 2+ or 3+), number of severe adverse events (binary: none vs. one or more), functional status (categorical: fully active, restricted in physically strenuous activity but ambulatory, ambulatory with full self-care vs. limited self-care, or completely disabled), body mass index < 18.5 kg/m², culture result (positive or negative), number of drugs in the regimen (count variable), prescription of cycloserine, and prescription of the following drugs that were likely to be effective in the patient: fluoroquinolone, linezolid, clofazimine, and a second-line injectable.